Patents by Inventor Akio Nishiura
Akio Nishiura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220258374Abstract: A tool set for manufacturing adhesive patches, by processing laminate web. The tool set includes a cutting tool having a cutting face lying in a cutting plane, and an embossing tool having a pressing face lying in a pressing plane, where the cutting plane and the pressing plane are parallel. The embossing tool is configured to press an edge area shape of the adhesive patch to be manufactured, and the cutting tool is configured to cut out the adhesive patch to be manufactured by cutting in edge area or outside the edge area. Furthermore, a method of manufacturing adhesive patches. The method essentially includes a feeding step, a pressing step and cutting step. Lastly an adhesive layering having a backing layer and an adhesive matrix layer. The backing layer having a larger size than the adhesive matrix layer.Type: ApplicationFiled: May 26, 2020Publication date: August 18, 2022Inventors: Markus Bee, Helena Gallinger, Alexander Saifert, Andreas Weber-Stebliwez, Georg Schlögel, Akio Nishiura, Akinori Sasaki, Masaoki Goto
-
Patent number: 9085523Abstract: The present invention provides a compound of which active |form| is represented by a formula (A). and which can be injected into a joint cavity which is an affected part of disorders and can be accumulated in the joint cavity to exert the pharmacological effect thereof in a sustained manner, for the purpose of ameliorating cartilage disorders without developing any side effect. A compound according to the present invention, which is represented by a formula (I): (wherein all of symbols are as defined in the description), is a compound that can achieve the above-mentioned purpose. This compound does not exhibit any side effect on the cardiovascular system even when the compound is administered in an effective amount for exhibiting a cartilage regeneration activity, and is therefore extremely useful as a safe and effective preventive and/or therapeutic agent for cartilage disorders.Type: GrantFiled: August 3, 2012Date of Patent: July 21, 2015Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Tetsuo Obitsu, Kousuke Tani, Hikaru Sugihara, Akio Nishiura, Shinsei Fujimura
-
Publication number: 20140171388Abstract: The present invention provides a compound of which active |form| is represented by a formula (A). and which can be injected into a joint cavity which is an affected part of disorders and can be accumulated in the joint cavity to exert the pharmacological effect thereof in a sustained manner, for the purpose of ameliorating cartilage disorders without developing any side effect. A compound according to the present invention, which is represented by a formula (I): (wherein all of symbols are as defined in the description), is a compound that can achieve the above-mentioned purpose. This compound does not exhibit any side effect on the cardiovascular system even when the compound is administered in an effective amount for exhibiting a cartilage regeneration activity, and is therefore extremely useful as a safe and effective preventive and/or therapeutic agent for cartilage disorders.Type: ApplicationFiled: August 3, 2012Publication date: June 19, 2014Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Tetsuo Obitsi, Kousuke Tani, Hikaru Sugihara, Akio Nishiura, Shinsei Fujimura
-
Patent number: 8642630Abstract: It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) I2 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) I2 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and/or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases.Type: GrantFiled: April 4, 2013Date of Patent: February 4, 2014Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Yoshiki Sakai, Akio Nishiura, Teppei Ogata
-
Patent number: 8436026Abstract: It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) 12 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) 12 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and/or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases.Type: GrantFiled: February 20, 2008Date of Patent: May 7, 2013Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Yoshiki Sakai, Akio Nishiura, Teppei Ogata
-
Patent number: 8410171Abstract: An adhesive preparation which has a pressure-sensitive adhesive layer comprising two components, i.e., a C1-4 alcohol ester of 4-{[2-((1R,2R,3R)-3-hydroxy-2-{(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-5-osocyclopentyl)ethyl]sulfanyl}butanoic acid and a silicone-based pressure-sensitive adhesive. This is an effective and safe preparation which is stable, shows little change in skin permability and release a drug not rapidly but continuously.Type: GrantFiled: October 25, 2007Date of Patent: April 2, 2013Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Akio Nishiura, Hikaru Sugihara, Kazuya Abe
-
Publication number: 20120202773Abstract: A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient. An EP4 agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).Type: ApplicationFiled: April 23, 2012Publication date: August 9, 2012Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Toru Maruyama, Kaoru Kobayashi, Tohru Kambe, Takayuki Maruyama, Hideyuki Yoshida, Akio Nishiura, Nobutaka Abe
-
Patent number: 8207223Abstract: A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient. An EP4 agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).Type: GrantFiled: August 27, 2009Date of Patent: June 26, 2012Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Toru Maruyama, Kaoru Kobayashi, Tohru Kambe, Takayuki Maruyama, Hideyuki Yoshida, Akio Nishiura, Nobutaka Abe
-
Publication number: 20100041758Abstract: An adhesive preparation which has a pressure-sensitive adhesive layer comprising two components, i.e., a C1-4 alcohol ester of 4-{[2-((1R,2R,3R)-3-hydroxy-2-{(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-5-osocyclopentyl)ethyl]sulfanyl}butanoic acid and a silicone-based pressure-sensitive adhesive. This is an effective and safe preparation which is stable, shows little change in skin permability and release a drug not rapidly but continuously.Type: ApplicationFiled: October 25, 2007Publication date: February 18, 2010Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Akio Nishiura, Hikaru Sugihara, Kazuya Abe
-
Publication number: 20100010222Abstract: A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient. An EP4 agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).Type: ApplicationFiled: August 27, 2009Publication date: January 14, 2010Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Toru MARUYAMA, Kaoru Kobayashi, Tohru Kambe, Takayuki Maruyama, Hideyuki Yoshida, Akio Nishiura, Nobutaka Abe
-
Patent number: 7547715Abstract: It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) I2 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) I2 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and/or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases.Type: GrantFiled: October 9, 2003Date of Patent: June 16, 2009Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Yoshiki Sakai, Akio Nishiura, Teppei Ogata
-
Publication number: 20090074844Abstract: The present invention relates to a blood concentration regulation type percutaneous absorption preparation, which comprises an ester form of 4-{[2-((1R,2R,3R)-3-hydroxy-2-{(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-5-oxocyclopentyl)ethyl]sulfanyl}butanoic acid and a base for external preparations. The blood concentration regulation type percutaneous absorption preparation of the present invention can stably maintain blood concentration of the active form of the present invention and is safe since there are no side effects. Therefore, it can be used as a percutaneous absorption preparation which can be persistently administered.Type: ApplicationFiled: April 27, 2006Publication date: March 19, 2009Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Akio Nishiura, Hikaru Sugihara, Harumi Arai, Toshiya Kanaji
-
Publication number: 20090022915Abstract: The present invention relates to a particle having a mean particle size of 0.01 to 20 ?m, containing tert-butyl (4R)-4-{[((1R)-2-[(1-benzylpiperidin-4-yl)amino]-1-{[(cyclohexylmethyl)thio]methyl}-2-oxoethyl)amino]carbonyl}-1,3-thiazolidine-3-carboxylate. A preparation containing the particle is excellent in pulmonary delivery through inhalation and is easy to handle because of excellent dispersibility of the particle, and thus the present compound can be used as a pulmonary preparation.Type: ApplicationFiled: March 8, 2006Publication date: January 22, 2009Applicant: ONO PHARMACEUTICAL CO., LTD.,Inventors: Hideo Masuda, Hikaru Sugihara, Akio Nishiura, Kazuyuki Hayashi
-
Publication number: 20080299089Abstract: It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) 12 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) 12 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and/or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases.Type: ApplicationFiled: February 20, 2008Publication date: December 4, 2008Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Yoshiki SAKAI, Akio Nishiura, Teppei Ogata
-
Publication number: 20080096924Abstract: To provide an amorphous composition for nasal administration or for administration by adhering to oral mucosa in which absorption property and chemical and physical stabilities of (2R)—N-(1-benzylpiperidin-4-yl)-3-cyclohexylmethylthio-2-[(4R)-3-tert-butoxycarbonylthiazolidin-4-ylcarbonylamino]propanamide which is useful as an N type calcium channel inhibitor are improved. A preparation comprising the amorphous composition of the present invention has been found to be excellent in physical stability and chemical stability and to be useful as a nasal preparation or a preparation for adhering to the oral mucosa. As a result, the resulting preparation has a high BA value and is useful for prevention and/or the treatment of a disease mediated by the N type calcium channel including pain (such as neuropathic pain, cancerous pain, intractable pain, postoperative pain, acute pain, chronic pain, neuralgia and infectious pain).Type: ApplicationFiled: December 16, 2005Publication date: April 24, 2008Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Hideo Masuda, Hikaru Sugihara, Akio Nishiura
-
Publication number: 20080033033Abstract: The pharmaceutical composition comprising the compound of the invention having 8-azaprostaglandin skeleton represented by formula (I) (wherein, all the symbols have the same meanings as that of the specification.) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EP4 agonistic action and thus are considered useful for the prevention and/or treatment of immunological diseases, asthma, neuronal cell death, arthritis, lung failure, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, shock and glaucoma, etc.Type: ApplicationFiled: May 16, 2007Publication date: February 7, 2008Inventors: Tohru Kambe, Toru Maruyama, Kaoru Kobayashi, Kousuke Tani, Yoshihiko Nakai, Toshihiko Nagase, Takayuki Maruyama, Kiyoto Sakata, Hideyuki Yoshida, Shinsei Fujimura, Akio Nishiura, Nobutaka Abe
-
Patent number: 7256211Abstract: The pharmaceutical composition comprising the compound of the invention having 8-azaprostaglandin skeleton represented by formula (I) (wherein, all the symbols have the same meanings as that of the specification) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EP4 agonistic action and thus are considered useful for the prevention and/or treatment of immunological diseases, asthma, neuronal cell death, arthritis, lung failure, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, shock and glaucoma, etc.Type: GrantFiled: January 20, 2004Date of Patent: August 14, 2007Assignee: ONO Pharmaceutical Co., Ltd.Inventors: Tohru Kambe, Toru Maruyama, Kaoru Kobayashi, Kousuke Tani, Yoshihiko Nakai, Toshihiko Nagase, Takayuki Maruyama, Kiyoto Sakata, Hideyuki Yoshida, Shinsei Fujimura, Akio Nishiura, Nobutaka Abe
-
Publication number: 20060122275Abstract: The present invention relates to reduction of side effects of diclofenac or a salt thereof An agent for reducing side effects of diclofenac or a salt thereof which comprises ornoprostil. It is expected that a combination agent of diclofenac or a non-toxic salt thereof and ornoprostil is comparable to even superior to marketed diclofenac tablets or Arthrotec tables in effects and fast-acting property while showing little side effects (particularly digestive disorders, gastric ulcer, diarrhea/vomiting and renal disorder) and exerting excellent antipyretic, analgesic and antiinlfammatory effects. Also, by formulating the combination agent into a preparation of separation type pharmaceutical preparation, the stability of ornoprostil can be improved.Type: ApplicationFiled: August 21, 2003Publication date: June 8, 2006Inventors: Yoshiki Sakai, Nobuo Katsube, Akio Nishiura, Masanobu Yamamoto, Ken-ichi Sugishita
-
Publication number: 20060069018Abstract: It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) I2 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) I2 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and/or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases.Type: ApplicationFiled: October 9, 2003Publication date: March 30, 2006Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Yoshiki Sakai, Akio Nishiura, Teppei Ogata
-
Publication number: 20050020686Abstract: A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient. An EP4 agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).Type: ApplicationFiled: July 22, 2002Publication date: January 27, 2005Inventors: Toru Maruyama, Kaoru Kobayashi, Tohru Kambe, Takayuki Maruyama, Hideyuki Yoshida, Akio Nishiura, Nobutaka Abe